Clinical Trial Update: Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria [Phase 3]

View source ↗

Summary

Phase 3 trial of ATM-AVI for serious infection due to MBL-producing Gram-negative bacteria was terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Serious Bacterial Infection

Drugs mentioned

• ATM-AVI

Snippet

Sponsor: Pfizer | Conditions: Serious Bacterial Infection | Phase 3 | Status: TERMINATED | Results posted: 2024-02-02